Grupo Biotoscana announces change in management
Montevideo, October 21st, 2019 – BIOTOSCANA INVESTMENTS S.A. today announced the appointment of Mr. Claudio Coracini as the new interim Chief Executive Officer of Grupo Biotoscana. Mr. Federico Wintour is leaving the company. Change will be effective immediately.
The Board of Director thanks Mr. Wintour for his contributions to the Company over the last year and congratulate Mr. Coracini on his new attributions.
“I am very pleased to have Coracini assuming this position during this transition period. He was the key driver of the transactional culture to integrate United Medical into GBT. And his experience, proven leadership and knowledge of the market and the company will certainly help GBT move on to this next phase”, said Juan Pablo Zucchini, Chairman of the Board of Directors.
Claudio has over forty years of experience in the pharmaceutical market, and, most importantly, he knows GBT and has been part of the team for the last 5 years. He was responsible for the Brazilian operations, leading the commercial structure, regulatory affairs, medical and compliance. During his management, United Medical was able to maximize the performance of the main products and launch 4 new innovative products in the country. Prior to joining GBT, Coracini worked at several pharmaceutical companies, such as Eli Lilly, Pfizer, Novo Nordisk and Shire. Claudio will be the interim CEO on this transition period and will accumulate the function of Country Manager of Brazil.
He holds a degree in Social Communication from Escola Superior de Propaganda e Marketing (ESPM), and a master’s degree in Marketing from ESPM.
“I have been with GBT for the last five years and I know about the great potential we have, so I am very excited with this new challenge supporting the whole group into the next chapter of the company“, said Claudio Coracini.
About GBT Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.